INmune Bio Return on Equity

INmune Bio (INMB) currently reports a ROE of -90.44%. That is below the Healthcare sector average of 22.01%. Use the charts on this page to explore INmune Bio's ROE history and peer comparisons.

INmune Bio's ROE of -90.44% is lower than the Healthcare sector average of 22.01%. That is roughly 510.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but INmune Bio's current -90.44% should be judged against Healthcare norms (sector average: 22.01%) and against INMB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -90.44%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for INmune Bio, and consider following INMB for alerts when major investors trade the stock.

INmune Bio is classified in the Healthcare sector. On ROE, it currently shows -90.44% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INMB with unrelated industries.